|
Real-time Estimate
Cboe BZX
15:19:27 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 2.565 USD | -7.07% |
|
-5.41% | +55.52% |
| 08-13 | Ovid Therapeutics Reports Pipeline and Business Updates | CI |
| 08-13 | Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Ovid Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 218.6 | 131.1 | 227.6 | 66.3 | 212.2 | 539 | - | - |
| Change | - | -40.04% | 73.64% | -70.87% | 220.05% | 154.02% | - | - |
| Enterprise Value (EV) | 218.6 | 131.1 | 227.6 | 66.3 | 212.2 | 539 | 539 | 539 |
| Change | - | -40.04% | 73.64% | -70.87% | 220.05% | 154.02% | 0% | 0% |
| P/E | 1.82x | -2.42x | -4.35x | -2.52x | -7.09x | -7.44x | -6.76x | -5.89x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 1.12x | 0.1x | 0.2x | -0.1x | -0.68x | -0.4x |
| Capitalization / Revenue | 1.05x | 87.2x | 581x | 117x | 29.3x | 658x | 2,414x | 2,004x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 658x | 2,414x | 2,004x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -7.64x | -6.28x | -5.21x |
| EV / FCF | - | - | - | - | -0x | -7.46x | -6.32x | -5.46x |
| FCF Yield | - | - | - | - | -18.1% | -13.4% | -15.8% | -18.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.76 | -0.77 | -0.74 | -0.37 | -0.23 | -0.371 | -0.408 | -0.4683 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 208.4 | 1.503 | 0.3917 | 0.566 | 7.252 | 0.8191 | 0.2233 | 0.269 |
| EBITDA | 124.4 | -55.04 | -57.68 | -60.18 | - | - | - | - |
| EBIT 1 | 149.2 | -55.55 | -59.28 | -61.88 | -42.44 | -70.56 | -85.77 | -103.4 |
| Net income 1 | 122.8 | -54.17 | -52.34 | -26.43 | -17.41 | -68.31 | -84.77 | -104.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.210 | 1.860 | 3.220 | 0.934 | 1.630 | 2.760 | 2.760 | 2.760 |
| Nbr of stocks (in thousands) | 68,092 | 70,467 | 70,681 | 71,010 | 130,184 | 195,298 | - | - |
| Announcement Date | 3/15/22 | 3/13/23 | 3/8/24 | 3/11/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.44x | - | - | - | 539M | |
| 21.8x | 7.74x | 15.55x | 1.36% | 74.27B | |
| 31.81x | 9.18x | 28.6x | 0.04% | 61.21B | |
| 31.83x | 6.79x | 17.62x | -.--% | 27.55B | |
| -73.75x | 14.26x | -68.76x | -.--% | 26.38B | |
| -15.46x | 5.96x | -7.5x | -.--% | 25.34B | |
| 28.48x | 5.36x | 17.82x | -.--% | 20.84B | |
| 1066.25x | 37.33x | 644.76x | -.--% | 14.94B | |
| 43.75x | 16.03x | 32.53x | 0.34% | 15.17B | |
| 17.96x | 5.35x | 12.5x | -.--% | 14.41B | |
| Average | 114.52x | 12.00x | 77.01x | 0.19% | 28.06B | |
| Weighted average by Cap. | 69.64x | 10.14x | 43.06x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OVID Stock
- Valuation Ovid Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
